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Abstract
Hepatitis C virus (HCV) is a progressive disease that infects more than 185 million in‐
dividuals worldwide and is associated with persistence of viral replication and ongo‐
ing necroinflammation and fibrosis. To date 20% of patients chronically infected with
HCV progress to cirrhosis. Epidemiological studies demonstrate that the incidence of
HCV is not well known, because acute infection is generally asymptomatic. The glob‐
al prevalence is about 2.2% and there is a large degree of geographic variability. Be‐
fore the 2011, the gold standard of therapy for the treatment of chronic hepatitis C
(CHC) was based on the combination of pegylated Interferon (peg-IFN) and Ribavirin
(RBV). However, several aspects related to safety profile limited their use in clinical
practice. In the recent years, thanks to basic research on HCV structure and replicative
cycle, it has been possible to develop direct acting antiviral drugs that have dramati‐
cally increased the viral clearance rate. Specifically, the advent of the triple therapy
employing direct acting antivirals has dramatically increased the viral clearance rate,
from less than 10%, with the initial regimen of IFN monotherapy, to more than 95%
with the current therapy. Even though new medications for hepatitis C are effective
disease modifiers and have the potential, in a long term perspective, to eradicate the
pathology, the cost of new treatments are unlikely to be sustainable for the NHSs. The
evidence documenting the effectiveness and tolerability of the new therapies for HCV
and several pharmacoeconomic analysis, shows that despite the cost, the new treat‐
ments can be considered cost-effective in the long period. However, the health care
systems are unable to compensate the height financial resources immediately needed
for treating patients with the long terms savings that will be obtained from the eradi‐
cation of HCV. Indeed, new pharmaceutical policy and a global commitment is re‐
quired to improve strategies of treatment and price negotiation with pharmaceutical
companies to move from a theoretical cost-effectiveness approach to a practical cost-
sustainable reality.
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1. Introduction
Hepatitis C virus (HCV) is a progressive disease that infects more than 185 million individuals
worldwide and is associated with persistence of viral replication and ongoing necroinflam‐
mation and fibrosis. To date, 20% of patients chronically infected with HCV progress to
cirrhosis.
Epidemiological studies demonstrate that the incidence of HCV is not well known since acute
infection is generally asymptomatic. The global prevalence is about 2.2%, and there is a large
degree of geographic variability. Before the 2011, the gold standard of therapy for the treatment
of chronic hepatitis C (CHC) was based on the combination of pegylated interferon (peg-IFN)
and ribavirin (RBV). However, several aspects related to safety profile limited their use in
clinical practice. In the recent years, thanks to basic research on HCV structure and replicative
cycle, it has been possible to develop direct acting antiviral drugs that have dramatically
increased the viral clearance rate. This new therapeutic strategy contemplates the use of
interferon-free treatment protocols that are shorter and well tolerated, and this might improve
the management of patients. These new medications for hepatitis C are effective disease
modifiers and could potentially eradicate the infection in a long-term perspective. However,
their costs are even high and unlikely sustainable for the National Health Systems (NHSs),
and new pharmaceutical policy and a global commitment are required for achieving the
universal access to new treatment strategies.
2. Structure and replicative cycle of HCV
The structure of the HCV virion remains poorly characterized despite several substantial
progress in biochemical and morphological studies, and most of the HCV proteins are now
actively being pursued as antiviral targets. HCV, discovered in 1989, is a positive-sense, single-
stranded RNA virus, approximately 9600 nt in length, which belongs to the Flaviviridae family
(Flavivirus genus), also including many arthropod-borne human pathogens such as yellow
fever virus, West Nile virus, and dengue virus. HCV has been classified by the World Health
Organization (WHO) as an oncogenic virus [1]. HCV-RNA encodes a polyprotein that is
cleaved by cellular and viral proteases into structural and nonstructural proteins, each with a
specific function. The structural proteins include two envelope glycoproteins E1 and E2, which
are targets of the host antibody response and are crucial for viral entry and fusion, and a core
protein (C), which interacts with the viral genome to form the nucleocapsid. The nonstructural
proteins P7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B form a complex with the RNA of the
virus to initiate viral replication, which occurs by budding through intracellular membranes.
Mature virions are released into the extracellular milieu by exocytosis, and nascent virions
incorporate cellular lipoproteins and apolipoproteins (e.g., apoE and apoB) as lipoviral
particles [2]. HCV specifically infects hepatocytes, entering the cells by receptor-mediated
endocytosis. During primary infection, HCV particles are transported by the blood stream and
come in contact with hepatocytes after spanning the fenestrated endothelium of the liver
sinusoids. In the Disse space, virions are in direct contact with the basolateral surface of
hepatocytes that interact with multiple cell surface molecules, including attachment factors
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and receptors. Upon cell surface attachment, the subsequent steps of HCV entry are only
partially known, but a putative mechanism has been described in analogy with other Flavi‐
viridae [3]. The virus/receptor complex is internalized, and the nucleocapsid is released into
the cytoplasm, decapsidated, and the free viral RNA is used for both polyprotein translation
and replication in the cytoplasm. Replication and posttranslational processing seem to take
place in a membranous site constituted by viral nonstructural proteins and host cell proteins,
the replication complex, located in close contact with the perinuclear membranes. Genome
encapsidation presumably takes place in the endoplasmic reticulum, and nucleocapsids are
enveloped and matured into the Golgi apparatus before the release of new virions in the
extracellular space by exocytosis [4]. There are seven main known genotypes (GT) of HCV
(from GT-1 to GT-7) that have been classified into 67 subtypes with distinct geographic
distributions, modality of transmission, and sensitivity to interferon-based treatments [5].
Estimates of genotype distribution within 98 countries show that the most widespread
genotype is the GT-1 (46%), with the subtypes 1a and 1b that are the most common in the
United States and in Europe, respectively. Afterward, there are the GT-3 (22%), frequent among
drug users; the GT-2 (13%), mainly present in the Mediterranean area; and the GT-4 (13%),
mainly present in Egypt and other Arabic countries. GT-7 is extremely rare, and the incidence
and prevalence are not yet known [5]. These seven genotypes are responsible for 97% of all
infections present worldwide [6]. Although there are no differences in the risk of cirrhosis
among all genotypes, GT-3 and GT-1b are associated with increased rate of hepatic steatosis
and of hepatocellular carcinoma, respectively [7]. In addition, all these genotypes show
different frequencies of polymorphisms associated with resistance to several classes of virus-
targeting drugs [8].
3. The role of immune response in HCV infection
HCV has a very high replicative capacity, and a viral titer of >106 IU/mL can be measured in
the serum within days after infection (averages 1–2 weeks) [9]. Innate immune response is the
first line of host defense during infection, and interferons (IFNs) are the family of cytokines
specialized in coordinating immunity against viruses and for the induction of an antiviral state
in cells, by activation and regulation of cellular components of innate immunity, such as
natural killer (NK) cells [10]. Furthermore, the induction of the endogenous IFN system in the
liver can be ineffective in clearing the infection and in preventing response to therapies with
peg-IFN and RBV [11,12]. Types I and II IFNs are in general the major elements of the innate
immune response against viruses [10]. Type III IFN family (also known as IFNs-λ) is composed
of interleukins (IL)-29, IL-28A, and IL-28B and is induced in response to several viral patho‐
gens. In the liver, type III IFN receptors are expressed at significant levels as a functional full-
length form, suggesting intact type III IFN signaling as part of the intrahepatic innate immune
response [13,14]. Genetic variants of the IFN-λ3 and IFN-λ4 locus are strongly associated with
spontaneous clearance of HCV and with response to therapy with peg-IFN and RBV. The
molecular mechanisms that link genetic variants near the IFN-λ4 gene with constitutive
activation of the endogenous IFN system in the liver are not entirely known, but it might
involve an ongoing stimulation of the JAK–STAT pathway by IFN-λ4 through the IFN-λ
receptors on hepatocytes. In contrast to the innate immune response, which is induced within
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hours to days after infection, the adaptive immune response against HCV is not detectable
before 6–8 weeks and involves all components of the adaptive immune system, i.e., humoral
antibodies, CD4+ T cells, and CD8+ T cells [10]. All these three components were shown to be
associated with viral clearance. A well-coordinated interaction of the different immune cells
might be essential for a successful immune response against HCV; however, little is known
about the precise dynamic of this cross-talk [15]. HCV-specific T cells are recruited to the liver,
and the viral replication is inhibited by both noncytolytic and cytolytic mechanisms. In about
20% of patients, the immune reaction during acute hepatitis C is strong enough to eliminate
the infection. Immunocompetent HCV-infected individuals produce antibodies against
epitopes within the structural as well as nonstructural proteins. Most of them, however, have
no relevant antiviral activity, and only a small fraction of antibodies is able to inhibit virus
binding, entry, or uncoating. These “neutralizing antibodies” target linear as well as confor‐
mational discontinuous epitopes mainly located within the envelope glycoproteins E1 and E2.
While strong data indicate the neutralizing activity of these antibodies in vitro, their efficiency
in vivo is less understood [10,15]. HCV elimination is associated with strong and sustained
CD4+ and CD8+ cell responses that target multiple epitopes within the different HCV proteins
and that remain detectable long after resolution of infection [10,16,17]. They act noncytolyti‐
cally, by secreting antiviral cytokines such as IFN-γ, as well as cytolytically, through perforin
secretion and by engaging the FAS/FAS-L pathway [15]. Despite the intervention of both innate
and adaptive immune response in CHC, the virus is able to escape from these barriers through
yet unknown mechanisms.
4. Epidemiology and world impact of HCV
HCV infection is one of the main causes of chronic liver disease worldwide, and according to
recent estimates, until now more than 185 million people around the world have been infected.
In addition, annually there are three million of new infected people, and among them 350,000
die every year due to HCV-related disorders [18–21]. The prevalence of HCV varies greatly,
depending on the geographical area and the population considered: in Western Europe, it
ranges from 0.4% to 3%; in Eastern Europe and the Middle East, it is higher but not precisely
known [22]. The majority of the infected people reside in Asian countries (Taiwan, Mongolia,
and Pakistan), sub-Saharan Africa (Cameroon, Burundi, and Gabon), and the Eastern Medi‐
terranean (Egypt), which holds the highest frequency, with more than 20% [18]. HCV is a major
global public health issue due to its high prevalence, long-term unpredictable disease pro‐
gression, and low diagnosis and treatment response rates. Despite the fact that HCV infection
rates are decreasing, the clinical and economic impact of chronic HCV infection is expected to
considerably grow in the next decade since a large population of individuals that acquired the
virus in the 1960s developed disease-associated health issues through to the 1980s [23]. The
dual therapy, based on the administration of peg-IFN and RBV, is successful only in 40–50%
of patients infected with the GT-1, while untreated individuals or who failed treatment are at
risk of developing severe liver injuries such as cirrhosis, liver transplantation, and hepatocel‐
lular carcinoma (HCC) [24]. In Europe, there are 30,000 people on the transplant waiting list
but only 12,000 procedures per year, and the average cost of liver transplant in the United
States varies between $139,000 and $400,000 [25]. Although HCV can be successfully treated
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by now using antiviral therapy based on the administration of new direct acting antivirals
(DAAs), the economic burden of the disease, including complex regimens and the cost of
treatment, remains high since health care costs continue to rise [26]. For this reason, many
HCV-diagnosed patients around the world are left untreated or undertreated. A 2010 study
performed on U.S. employments found that the cost of sick days and lower productivity per
HCV-infected workers was US$8,352 per year [25]. A U.S. survey by the American Gastroen‐
terological Association (AGA) indicated that the cost for 30,000 outpatient visits for HCV
infection amounted to US$24 million in the 1998 [27]. The median cost for treating one patient
with dual therapy (peg-IFN and RBV) ranges from €7,517 to €21,229, depending on the virus
genotype, plus the costs of the new DAAs are about US$70,100 per quality-adjusted life years
(QALY) for mild fibrosis and US$36,300 per QALY for advanced fibrosis [28].
5. Natural history of HCV infection
HCV transmission primarily occurs via parenteral routes. Before the 1990s, the main routes of
transmission were unsafe blood transfusion procedures and injecting drug use. Currently, new
infections are mainly due to the use of drugs and, to a lesser extent, to unsafe medical and
surgical procedures, tattoos, and piercings. Distinctive HCV genotype distribution and
prevalence worldwide are due primarily to differences in transmission routes and clinical care
(Table 1) [29,30].
Patients
People who have received blood transfusions and solid organ transplant before 1992, or coagulation factor before 1987,
or in countries where serological testing of blood donations for HCV is not routinely performed
Patients exposed to nosocomial infections such as employees in hemodialysis centers
Recipients of previously unscreened blood, blood products, and organs
Hemophiliacs
People with HIV infection
People exposed to unsterile medical or dental equipment in health care settings where infection control practices are
substandard
Workers and other categories
Health care workers with occupational exposure to blood
Infants born from HCV-infected mothers
Injecting drug users and people using intranasal drugs
People receiving tattooing, body piercing, scarification procedures, and/or acupuncture with unsterile material
Prisoners
Sexual and household transmission are possible
10–40% with no identifiable risk factor
Table 1. Populations with high HCV prevalence or who have a history of HCV risk exposure/behavior
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Acute HCV infections are often oligo- or asymptomatic. The long incubation period makes
difficult to link related cases to the source of infection, and despite the high prevalence of
disease, most infected people are unaware of their infection. The long-term impact of HCV
infection is highly variable, ranging from minimal histological changes to extensive fibrosis
and cirrhosis with or without HCC [31]. Spontaneous clearance in the chronic phase of the
infection is rare and occurs only in 15–25% of cases. In 70–80% of infected patients, the virus
persists and the infection becomes chronic. In most patients, CHC leads to different degrees
of liver fibrosis, and one third (15–25%) of them could develop liver cirrhosis and HCC at a
rate of 2–4% after 10 to 40 years (Figure 1) [10,18]. The progression of liver disease occurs over
decades and is accelerated by alcohol consumption, diabetes/obesity, coinfections (human
immunodeficiency virus [HIV] and hepatitis B virus), old age at the time of infection, cumu‐
lative exposure to hepatotropic viruses, and environmental hepatotoxins [32,33]. The extra‐
hepatic manifestations of HCV infection include cryoglobulinemia, membranous
glomerulonephritis, and some non-Hodgkin lymphomas [34]. In Europe, about 1/4 of HIV-
infected patients have an HCV coinfection. Patients coinfected with HIV/HCV have a higher
risk of cirrhosis and AIDS and a higher overall mortality [35]. Thanks to the growing knowl‐
edge on the pathophysiology of the disease, the development of diagnostic procedures, and
the improvements in therapy and prevention, the clinical care for patients with HCV-related
liver disease has considerably advanced during the last years.
Figure 1. Natural history of HCV infection. In patients with HCV infection, the spontaneous clearance after the acute
phase occurs only in 15–25% of cases; during the chronic phase, extrahepatic manifestations might occur. For patients
who progress to decompensated cirrhosis, the survival rate at 5 years is about 50%, and among them, 2–4% per year
develop hepatocellular carcinoma
6. Screening and diagnosis
Since many infected people are unknown to health care systems due to the asymptomatic
nature of the disease, the management of HCV infection should focus not only on therapy but
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also on the screening of carrier individuals in order to prevent transmission [36]. In the case
of a newly acquired infection, the diagnosis of CHC can be made 4–6 months after viral
infection [30]. The HCV serologic testing should be offered to individuals who are part of a
population with high HCV seroprevalence or who have a history of HCV risk exposure/
behavior. It is also important to consider the possibility of infection with other blood-borne
viruses in subjects with HCV, and to offer screening for tuberculosis, hepatitis B virus, and
HIV, especially in some groups at risk, such as prisoners and people who inject drugs [18,26].
The current diagnostic techniques for HCV infection are based on a range of tests, including
the detection of anti-HCV by enzyme immunoassay in the majority of patients. The test for
HCV-RNA by real time polymerase chain reaction is considered the best technique to confirm
the presence of viremia and represent the gold standard in HCV diagnosis [lower limit of
detection <15 international units (IU)/mL] playing a crucial role in patient management and
for choosing the best therapeutic regimen [30,31].
Following spontaneous or treatment-induced viral clearance, anti-HCV antibodies persist in
the absence of HCV RNA but might decline and finally disappear in some individuals [37,38].
Additional tests include HCV genotype and subtype determination and host genetics. The
improved safety and efficacy of the new DAAs across genotypes could allow a simplified
approach to pretreatment screening, without requiring further baseline tests [39].
7. Assessment of liver disease severity
Due to the particularly high cost of the new DAAs, in the last 3 years, the access to treatment
has been restricted and strictly regulated. For this reason, the decision regarding treatment
initiation with DAAs mainly focus on the assessment of liver disease severity. In particular,
individuals at more advanced stages and with compensated cirrhosis benefit more than people
with less advanced cirrhosis since they are at higher dying risk.
Well-established panels of direct and indirect biomarkers have been studied for the assessment
of fibrosis progression and for the diagnosis of cirrhosis. Indirect biomarkers reflect liver
function while direct biomarkers reflect extracellular matrix turnover and include many
molecules involved in hepatic fibrogenesis. The most commonly used indirect serum bio‐
markers comprise the following: (i) the AST platelet ratio index [APRI = (AST/upper limit of
normal)× 100/platelet count] that was extensively validated in chronic HCV; (ii) Fibrotest, a
patented biomarker panel using five biochemical markers and two clinical parameters, which
was validated in several etiologies of cirrhosis and in the monitoring of fibrosis progression;
and (iii) FIB4, a biomarker panel using age, AST, platelet count, and ALT [FIB4 = (age× AST) /
(platelets × √ALT)], originally developed and validated in a cohort of HIV/HCV-coinfected
patients [40]. The blood tests needed for calculating APRI and FIB4 scores are inexpensive and
are available at the health facilities that provide treatment for HCV infection since they are
also used to monitor patients before and after the commencement of treatment [18,26]. Liver
biopsy remains the reference method for grading the activity and histological progression
(staging) of the disease [30,31,41]. However, because of its invasiveness, patient discomfort,
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risk of complications, as well as the need for expert histological interpretation, transient
ultrasound elastography (Fibroscan) is now used to assess liver disease severity prior to
therapy at a safe level of predictability [42,43]. Fibroscan is a noninvasive method of measuring
the mean stiffness of hepatic tissue, with hepatic rigidity considered a marker of progressive
fibrosis. There are different scoring systems for assessing the severity of chronic liver disease.
The major approach to classify CHC involves three separate considerations: (1) the etiology,
which is determined on the basis of histological appearance and laboratory tests; (2) the
severity and distribution of necroinflammatory activity; and (3) the degree of fibrosis [44]. The
most common scoring methods to interpret a liver biopsy include the Metavir, the histologic
activity index (HAI), also known as Knodell score, and the modified hepatic activity index
(Ishak-modified Knodell score) [45].
Metavir is a scoring system used to assess inflammation and fibrosis by histopathological
evaluation of a liver biopsy of patients with HCV. The scoring from A0 to A3 represents a
grading system that gives an indication on the activity and degree of inflammation. The
amount of inflammation is relevant since it is considered a precursor of fibrosis (Table 2).
Metavir also includes a staging system that indicates the amount of fibrosis or scarring [46].
The Knodell score is a semiquantitative and reproducible histological scoring of liver biopsies,
also commonly used for staging liver disease, that includes three categories of necroinflam‐
matory activity: periportal injury with or without bridging necrosis, lobular injury, and portal
inflammation. Lesions are assigned weighted numeric values that resulted in a combined
score, the hepatic activity index (HAI) [47].
In the last years, the Knodell score has been partially replaced by the Ishak score, in which the
major changes concern the modification of the HAI and the further division of necroinflam‐
matory assessment in four categories [45].
Activity grade A0 A1 A2 A3
Definition No activity Mild activity Moderate activity Severe activity
Fibrosis stage F0 F1 F2 F3 F4
Definition No fibrosis Portal fibrosiswithout septa
Portal fibrosis with few
septa
Numerous septa
without cirrhosis Cirrhosis
Table 2. Metavir liver biopsy scoring system
8. Predictors of treatment response to HCV
Several patient and viral-related factors that can affect the severity of the disease, its progres‐
sion, and treatment outcome have been identified. The chronicity rate in HCV infection
appears to be lower in young individuals, and several studies highlight that young age (age
<40 years) is associated with more sustained virological response (SVR) [33,48]. The female sex
is associated with a higher SVR rate than that of males, using the standard peg-IFN and RBV
dual therapy [49]. Obesity is also a relevant predictor of disease progression, and prospective
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studies report that a body mass index of 25 kg/m2 was associated with significant progression
in the extent of fibrosis [50]. Furthermore, insulin resistance is extremely common in patients
with chronic HCV infection and has been associated with increased disease severity, extrahe‐
patic manifestations, and decreased response to antiviral therapy [51]. Many epidemiological
studies showed an association between chronic HCV infection and the risk of developing type
1 and type 2 diabetes mellitus [52]. Taking into account the viral factors, HCV genotype is the
strongest baseline predictor since there is a close correlation between the different genotypes
and sensitivity to IFN-based therapies. GT-1 and GT-4 are intrinsically more resistant to IFN-
α than GT-2 and GT-3, and for this reason, the viral clearance in patients who are IFN res‐
ponders occurs much slower in GT-1 and 4, as compared to 2 and 3 [53]. Although viral load
does not correlate with the severity of liver injury or the progression of the disease, a low
baseline viral load (<600,000 IU/mL) is related with the SVR and the treatment outcome [54].
Genetic variations have long been sought to explain the differences in host antiviral response,
and it is now well established that host genetics plays a role in the response to IFN-based
therapy in HCV infection [55]. A number of polymorphisms related to the IFN gene (IL28B)
have been involved in the immune response to HCV and appear to be strongly associated with
SVR in all groups of patients [56]. There are three IL28B distinct genotypes known as CC, CT,
and TT, which are strongly associated with race/ethnicity. People with the CC genotype have
a stronger immune response to HCV infection than people with the CT or TT genotypes (called
non-CC genotypes), and this polymorphism is strongly associated with a greater likelihood of
spontaneous viral clearance [57]. In the context of peg-IFN/RBV therapy, the IL28B genotype
could assist clinical decision making for the treatment of HCV infection. The first generation
of DAAs, including nonstructural NS3/4A protease inhibitors, has shown promising outcomes
when used in combination with peg-IFN/RBV in several clinical trials on GT-1-infected
patients, with an SVR higher than the dual therapy [58,59]. The SVR rates in the SPRINT-2 and
ADVANCE trials were higher in patients with CC (80% and 90%, in the two trials, respectively)
compared with CT (71% and 71%) or TT (59% and 73%) [60–62]. It is not yet clear if IL28B
polymorphism could still affect the treatment outcome with the interferon-free regimen since
larger cohort sizes will be required to confirm its influence.
9. Current standard of care and future therapies for HCV infection
In the past few years, HCV therapy has quickly changed the natural history of this disease.
Before 2011, the gold standard of therapy was based on the combination of peg-IFN and RBV
that, however, acts by unspecific and not completely known mechanisms and exhibited low
efficacy in some subgroup of population. The improvement of the knowledge on HCV life
cycle allowed to identify innovative therapeutic targets and to develop new drugs known as
direct acting antivirals (DAAs). These drugs target three of the main proteins involved in viral
replication: the NS3/4A protease, the NS5B polymerase, and the NS5A. The addition of DAAs
to peg-IFN and RBV and the development of new interferon-free regimen have dramatically
increased clinical outcome leading SVR rates from 90 to 100% (Figure 2).
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Figure 2. HCV protein products, mechanism of action, and activity of anti-HCV drugs. NIs: nucleoside inhibitors;
NNIs: nonnucleoside inhibitors; n.a.: not available.
9.1. Endpoints of treatment
The goal of HCV therapy is to eradicate infection, thus limiting or preventing the development
of disease complications. The most important endpoint, accepted by regulatory agencies for
assessing the efficacy of the therapy, is the sustained virological response (SVR) (Table 3). SVR
is defined as undetectable HCV RNA 12 weeks (SVR12) or 24 weeks (SVR24) after treatment
completion. Achieving this result is associated with a reduced risk of disease progression in
patients without cirrhosis, while those with cirrhosis remain at risk of life-threatening
complications [30,31].
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Responses to therapy Features
Rapid virological response Undetectable HCV RNA levels at week 4 of therapy, maintained until the end oftreatment
Extended rapid virological response Undetectable HCV RNA levels at weeks 4 and 12
Early virological response HCV RNA detectable at week 4 but undetectable at week 12, maintained untilthe end of treatment
Delayed virological response More than 2 log10 drop but still detectable HCV RNA at week 12, andundetectable at week 24, maintained until the end of treatment
Sustained virological response Undetectable HCV RNA levels (<50 IU/mL), 24 weeks after completion oftreatment
Partial response More than 2 log10 IU/mL decrease in HCV RNA level from baseline at week 12of therapy but still detectable at weeks 12 and 24
Null response Less than 2 log10 IU/mL decrease in HCV RNA level from baseline at week 12of therapy
Relapse Undetectable HCV RNA levels at the end of treatment but detectable at anytime within 24 weeks of follow-up
Breakthrough Reappearance of HCV RNA at any time in the course of treatment
Table 3. Definition of responses to therapy according to the European Association for the Study of the Liver (EASL)
(extracted from Conteduca et al. [75]).
9.2. Dual therapy: Pegylated-interferon and ribavirin
Until recently, the combination of peg-IFN and RBV was the “historical” standard of care for
patients with HCV, and many regimens still contain one or both of these agents [8]. The IFNs
are a family of proteins, naturally produced by cells of the immune system with antiviral,
antiproliferative, and immunomodulatory activities. After administration, IFNs bind specifi‐
cally to high-affinity receptors that are present on the surface of most cells, triggering a cascade
of intracellular signaling responsible for the antiviral functions and immunomodulatory
effects that enhance the host-specific antiviral immune responses [63]. However, in clinical
practice, the efficacy of IFN is limited by short half-life and frequent administration (at least
three times weekly, even better daily). These limitations have been resolved by developing a
modified IFN conjugated with the polymer polyethylene glycol (peg). The introduction of
pegylated forms of IFN-α has substantially improved SVR rates and pharmacokinetic profile,
allowing once-weekly dosing without changing the safety profile [64]. RBV is an oral guano‐
sine analog with broad antiviral activity against several RNA and DNA viruses. The exact
mechanism of action has not yet been totally elucidated, although several hypotheses suggest
that its biological action occurs through modest inhibition of viral replication, depletion of
cellular guanosine triphosphate, immunomodulatory effects, and possible induction of viral
mutagenesis [65]. The duration of combined therapy depends on genotype, viral load, and
stage disease, with variable regimens from 24 to 48 weeks. Results from clinical practice
showed that 45% of patients with GT-1 and GT-4 infection, 70–80% of those infected with GT-2
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or GT-3, and 45–70% of patients with other genotypes achieved the SVR [66–72]. However,
there were several limitations in treating patients with peg-IFN and RBV due to drug toxicities,
low tolerability, or low efficacy (many patients do not respond or became intolerant) [69,70].
The safety profile is one of the limitations leading to dose reduction or treatment discontinu‐
ation. Adverse events caused by peg-IFN are fatigue, flu-like symptoms, depression, anemia,
neutropenia, and thrombocytopenia, while those caused by RBV are blood and lymphatic
disorder, nausea and vomiting, headache, anorexia, rash, and skin irritation [24,69].
9.3. NS3/4A inhibitors class
Protease inhibitors (PIs) act through reversible and covalent inhibition of the serine protease
NS3/4A responsible for processing of HCV polyprotein and production of new infectious
virions (Figure 2). These drugs can be structurally divided into two groups: linear tetrapeptide
α-ketoamide derivatives and macrocyclic inhibitors. Generally, PIs have a remarkable antiviral
activity and a low barrier to resistance and are selective against GT-1 infection. Furthermore,
the most NS3/4A inhibitors interact with the cytochrome CYP3A4, one of the main enzymes
responsible for drug metabolism, and this results in increased drug–drug interactions that can
limit treatment regimen [8,73]. These limitations have been partially overcome by the advent
of a new generation of PIs, which are also effective against genotypes other than the GT-1, and
possess a higher barrier to viral resistance as well as lower propensity for toxicity and drug–
drug interactions [8,74].
9.3.1. Telaprevir and Boceprevir
Telaprevir and boceprevir are the first generation of PIs approved by the Food and Drug
Administration (FDA) and the European Medicines Agency (EMA). Telaprevir and boceprevir
have been licensed in combination with peg-IFN and RBV, for the treatment of GT-1 infection
in naive and experienced patients with compensated liver disease. Telaprevir and boceprevir
improved SVR from 49% to 75% in naive patients as compared to the dual therapy [7,75].
Although these therapies have increased clinical outcome, their use is limited by increased rate
of adverse effects, including hemolymphopoietic disorders and other reactions related to
gastrointestinal system (nausea, diarrhea, vomiting, hemorrhoids, proctalgia, and pruritus).
Furthermore, the drugs have a low genetic barrier to resistance [68] and extensive drug–drug
interactions that limit their use in transplanted or coinfected patients [76–78].
9.3.2. Simeprevir
Simeprevir is a once-daily, second-wave protease inhibitor, licensed recently by the FDA and
the EMA. This agent is indicated in association with peg-IFN and RBV for the treatment of
GT-1 and GT-4 infection. This drug can be associated with sofosbuvir regardless of prior
patient treatment history [79]. Simeprevir has a broad spectrum of activity against multiple
HCV genotypes except for GT-3 [80]. Data from different trials show that it is highly effective
and well tolerated. The most common adverse events are nausea, rash, pruritus, dyspnea,
increment in bilirubin blood levels, and photosensitivity [8,74,79]. The NS3 Q80K polymor‐
phism is commonly found in GT-1a viruses and is associated with resistance in vitro and
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impaired response to simeprevir. It is therefore recommended that patients infected with
GT-1a must be screened for the presence of Q80K to evaluate the use of another agent in case
of positive result [81]. The activity of simeprevir has been validated in several phase II/III
studies: QUEST I, QUEST II, PROMISE, ASPIRE, and RESTORE.
In the QUEST I and QUEST II studies, 785 naive patients with GT-1 infection were randomized
to placebo or simeprevir plus peg-IFN and RBV for 12 weeks. Eighty percent of patients treated
with simeprevir achieved SVR12 compared with 50% in the placebo arm [81,82]. The PROMISE
study randomized 393 relapsers with GT-1 infection to simeprevir or placebo for 12 weeks
with peg-IFN plus RBV or RBV alone for additional 12–36 weeks, on a response-guided therapy
basis. In this trial, 79% of simeprevir treated patients achieved an SVR at 12 weeks compared
with 37% of patients in the placebo arm [83]. The efficacy of simeprevir in patients with GT-1
infection was evaluated also in the ASPIRE study that confirmed these results [84]. Finally, in
the RESTORE trial, the efficacy of simeprevir in GT-4 infection was established [85].
9.3.3. Paritaprevir
Paritaprevir is an NS3/NS4A protease inhibitor that has been licensed by the FDA and the
EMA in combination with ritonavir, ombitasvir, and dasabuvir with or without RBV. Pari‐
taprevir is metabolized primarily by cytochrome CYP3A4 and is used in combination with
ritonavir, a potent CYP3A4 inhibitor, in order to improve the exposures at acceptable dosing
frequency [86,87].
9.4. NS5A inhibitors class
The nonstructural NS5A protein is critical for the virus functions, having a role in viral
replication and assembly, and performing complex interactions with cellular functions.
Because of this crucial role, NS5A has been identified as a suitable target for viral inhibition
(Figure 2). NS5A inhibitors have a high antiviral potency, a pan-genotypic activity, and a
genetic barrier to resistance from medium to high. They also possess a good pharmacokinetic
and a safety profile that allow once-daily dosing [8,75,88]. Although several NS5A inhibitors
are in clinical development or already approved, the exact mechanism is not yet completely
known [89]. Recent evidence reported that some of these drugs inhibit formation of the
membranous web (Figure 2) that is thought to be the site of viral RNA replication [88,90]; other
hypotheses suggest that NS5A inhibitors induce rearrangement of NS5A from endoplasmic
reticulum-derived foci and limit hyperphosphorylation of this nonstructural protein [91–93].
9.4.1. Daclatasvir
Daclatasvir is the first NS5A inhibitor that is active at picomolar concentrations with broad
coverage of HCV genotypes [89]. Daclatasvir has been recently approved in combination with
sofosbuvir with or without RBV for the treatment of GT-1, GT-3, and GT-4 chronic hepatitis C
in naive and experienced patients. Daclatasvir has a pharmacokinetic profile that allows once-
daily dosing, and a low potential of causing drug–drug interactions with other medications
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[94]. Daclatasvir was studied in various combinations with NS3 and NS5B inhibitors and with
peg-IFN and RBV.
In a phase II study, 395 naive patients with GT-1 and GT-4 infection were randomized to receive
two doses of daclatasvir (20 or 60 mg) in combination with peg-IFN and RBV compared with
peg-IFN and RBV plus placebo. The SVR24 was achieved by 59.2% of patients receiving 20 mg,
59.6% in those who received 60 mg, and 37.5% in the placebo group. In patients with GT-4
infection, the SVR24 was achieved by 66.7% and 100% of those who received 20 mg or 60 mg
daclatasvir, respectively, vs 50.0% in the placebo group [95].
In the COMMAND trial, 151 treatment-naive patients with GT-2 and GT-3 infection were
randomly assigned to receive daclatasvir or placebo plus peg-IFN and RBV for 24 weeks.
SVR24 was achieved by 83% in GT-2 infection and by 69% in GT-3 infection, vs 63% in control
arm [96]. The treatment is well tolerated, and the main adverse events reported are diarrhea,
fatigue, headache, and nausea. The most significant resistant associated variants are 31V and
Y93H for GT-1b, and 31V, Y93H M28, and Q30 for GT-1a [97].
9.4.2. Ledipasvir
Ledipasvir is a potent NS5A inhibitor against GT-1, GT-4, and GT-5 infection but has lower
activity against GT-2 and GT-3 infection [89]. Ledipasvir was recently approved in combina‐
tion with sofosbuvir with or without RBV for the treatment of GT-1-, GT-3-, and GT-4-infected
patients, naive or experienced, and for the advanced liver disease [98]. This combination is one
of the most emerging interferon-free therapies that present a better safety profile than standard
therapy and an elevated efficacy with SVR rates from 90% to 100%.
9.4.3. Ombitasvir
Ombitasvir is a novel potent NS5A inhibitor with a promising efficacy particularly in difficult-
to-treat patients, in association with other DAAs [99]. This drug has been licensed by the FDA
and the EMA in combination with paritaprevir/ritonavir and Dasabuvir with or without RBV.
The efficacy of this drug was proved in several clinical trials both in association with peg-IFN/
RBV and in interferon-free regimens. In a study of treatment-naive GT-1-infected patients,
ombitasvir in combination with peg-IFN and RBV showed an early virological response in 25
out of 28 patients receiving the NS5A inhibitor compared with 6 out of 9 patients in the placebo
group [89,99,100].
9.5. NS5B inhibitors class
NS5B protein is responsible for replication of HCV RNA and represents one of DAAs thera‐
peutic target (Figure 2). NS5B RNA polymerase inhibitors can be divided into two distinct
categories: the nucleoside inhibitors (NIs) and the nonnucleoside inhibitors (NNIs). NIs act by
binding to the active site of the enzyme and are integrated into the growing RNA chain, causing
chain interruption. Nonnucleoside inhibitors (NNIs) bind outside the active site, leading to
the allosteric inhibition of RNA polymerase activity [8,75]. NIs have pan-genotypic activity
and a medium–high barrier to resistance; NNIs have a low–medium activity against different
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HCV genotypes as well as a low barrier to resistance. These differences are explicated on the
basis of different mechanisms of action because NIs act in a highly conserved region of the
HCV genome while NNIs bind only one of the four binding sites, and this results in a lower
efficacy against the different HCV genotypes [7,75].
9.5.1. Sofosbuvir
Sofosbuvir is the first NI approved by the FDA and the EMA in combination with other
antiviral drugs for the treatment of all HCV genotypes in adults [101]. Recently, sofosbuvir
was approved as a fixed-dose combination in a single tablet with ledipasvir [98]. Sofosbuvir
has a potent activity against all HCV genotypes, a high barrier to resistance, an excellent
tolerability, and a very favorable pharmacokinetic profile. The addition of sofosbuvir to peg-
IFN and RBV did not increase the frequency or severity of side effects [101,102]. The main
adverse events reported in clinical trials are fatigue, headache, and nausea. In vitro resistance
is linked to the development of an S282T mutation in the NS5B gene, although this should be
confirmed in higher numbers of patients [7,8]. The efficacy of sofosbuvir was evaluated in
patients infected with GT-1 to GT-6 chronic hepatitis C and was licensed on the basis of the
following three studies: NEUTRINO, PROTON, and ATOMIC.
The NEUTRINO was a phase III, single-arm study that investigated the efficacy and safety of
sofosbuvir with peg-IFN and RBV in 327 naive patients with GT-1, GT-4, GT-5, or GT-6
infection. SVR rates at 12 weeks were 90% for GT-1 infection, 97% for GT-4/GT-5/GT-6
infections, and 80% in patients with cirrhosis [103]. In the PROTON study, 147 GT-1-infected
patients were treated with sofosbuvir or placebo in combination with peg-IFN and RBV for 12
weeks. SVR12 rates were achieved by 91% in sofosbuvir arm and 58% in the placebo group
[8,104]. Finally, results from ATOMIC study confirmed the high efficacy of sofosbuvir in these
populations [105]. The introduction of this drug in clinical practice has changed the clinical
outcome achieving SVR over 90% especially in difficult to treat population as the GT-1-infected
one.
9.5.2. Dasabuvir
Dasabuvir is a nonnucleoside inhibitor and will be used as a part of the all-oral interferon-free
HCV therapy in combination with ombitasvir and paritaprevir/ritonavir. This combined
therapy has been recently approved by the FDA and the EMA. This combination has shown
high efficacy in several clinical trials and is one of the most promising interferon-free regimen.
Dasabuvir was developed to treat GT-1-infected patients while is inactive toward GT-2, GT-3,
and GT-4 infection. Dasabuvir is well tolerated, and the main adverse events recorded, when
in combination with other DAAs, were mild such as headache and fatigue [106,107].
9.6. Future therapies for HCV infection: interferon-free regimen
During the last year, the advent of interferon-free regimen has dramatically changed the
standard of care of anti-HCV therapy. These therapies include molecules with different
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mechanisms of action, pan-genotypic activity that improve their safety, and efficacy profile,
simplifying treatment duration. Several interferon-free combinations have been recently
approved, and other trials are in ongoing with different DAAs. Results from recent clinical
studies established that a permanent cure from infection could be achieved with interferon-
free combinations [20].
9.6.1. Sofosbuvir plus ribavirin
Sofosbuvir was the first drug licensed by the FDA and the EMA as part of interferon-free
regimen. Currently, sofosbuvir is indicated in combination with RBV for the treatment of
patients with GT-2 and GT-3 infection, even at advanced stages of the disease, while for all the
other genotypes, it is recommended only in patients ineligible or intolerant to peg-IFN.
Sofosbuvir-based treatment has been evaluated in several clinical trials [101]: FISSION,
POSITRON, VALENCE, and FUSION.
FISSION was a randomized study that evaluated 12 weeks of treatment with sofosbuvir and
RBV compared with 24 weeks of treatment with peg-IFN and RBV in 499 treatment-naive
patients with GT-2 or GT-3 infection. The SVR rates were 95% and 56% in GT-2- and GT-3-
infected patients, respectively, for the treatment with sofosbuvir/RBV, vs 78% and 63% in the
peg-IFN/RBV arm [103]. POSITRON study confirmed the clinical results obtained in FISSION
study [108].
In the FUSION trial, the combination of sofosbuvir/RBV was evaluated in GT-2- or GT-3-
infected patients, nonresponders to prior interferon-based treatment. SVR rates were 86–94%
in patients with GT-2 infection and 30–62% in GT-3 infection, for 12 or 24 weeks of treatment,
respectively [108]. The results obtained in the FISSION study for patients with GT-2 or GT-3
infection have been confirmed by the VALENCE trial [109].
Based on these studies, the combination of sofosbuvir and RBV showed high efficacy with SVR
>90% in patients with GT-2 infection, while lower SVR rates were recorded in patients with
GT-3 infection. This last population remains the most challenging group of patients to treat
with interferon-free regimen.
9.6.2. Sofosbuvir/ledipasvir ± ribavirin
Recently, the FDA and the EMA approved the fixed combination of sofosbuvir/ledipasvir with
or without RBV for 12 or 24 weeks for the treatment of GT-1, GT-3, and GT-4 chronic hepatitis
C in naive and experienced patients and in patients who had liver peritransplant [98]. The
efficacy of sofosbuvir/ledipasvir was evaluated in three phase III studies: ION-3, ION-2, and
ION-1.
The phase III ION-3 study evaluated 8 weeks of treatment with ledipasvir/sofosbuvir with or
without RBV and 12 weeks of treatment with ledipasvir/sofosbuvir, in 647 treatment-naive
noncirrhotic patients with GT-1 infection. The SVR12 was 94% in ledipasvir/sofosbuvir, 93%
ledipasvir/sofosbuvir plus RBV in patients who received 8 weeks, and 95% in patients who
received 12 weeks of ledipasvir/sofosbuvir. These results showed no benefits with the addition
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of RBV in the regimen or with extension of the treatment duration to 12 weeks [110]. A similar
rate of SVR was achieved in experienced patients with GT-1 infection in ION-2 and ION-1
studies, with clinical outcome ranging from 94% to 99% for subjects treated with ledipasvir/
sofosbuvir ± ribavirin [111,112]. The treatment is well tolerated, and the most common side
effects are fatigue and headache [98].
9.6.3. Sofosbuvir plus daclatasvir ± ribavirin
The combination of sofosbuvir plus daclatasvir with or without RBV for 12 or 24 weeks was
evaluated in the AI444040 study in 211 patients infected with GT-1, GT-2, or GT-3, including
treatment-naive individuals and who had failed prior therapy with boceprevir or telaprevir.
SVR12 was achieved in 98% naive and experienced patients with GT-1 infection, 96% of those
with GT-2 infection and 89% of those with GT-3 infection. The treatment was well tolerated,
and the most common adverse events reported are fatigue, nausea, and headache. This results
indicated that sofosbuvir plus daclatasvir is efficacious in GT-1-, GT-2-, or GT-3-infected
patients and in nonresponders with GT-1 infection [94,113]. This therapeutic approach is now
being tested in a phase III study, in subjects with GT-3 infection [114].
9.6.4. Sofosbuvir plus simeprevir ± ribavirin
The safety and efficacy of combined oral sofosbuvir plus simeprevir was evaluated in the
COSMOS study. In this trial, 168 patients (treatment-naive patients and previous nonrespond‐
ers) were randomized in two cohorts on the base of METAVIR scores (F0–F2 in cohort 1, F3–
F4 in cohort 2) to receive 12 or 24 weeks of simeprevir and sofosbuvir with or without RBV.
SVR was achieved by 92% in cohort 1 and 94% in cohort 2. This study suggested that the
addition of RBV and treatment duration for 24 weeks did not clearly improve SVR rates. This
combination therapy was well tolerated, and the most common adverse events were fatigue,
headache, and nausea [115].
9.6.5. 3D regimen: paritaprevir/ritonavir, ombitasvir, dasabuvir ± ribavirin
The multitarget therapy, which includes all-oral combination of paritaprevir/ritonavir,
ombitasvir, and dasabuvir, is one of the most promising interferon-free therapies. Paritaprevir/
ritonavir and ombitasvir are coformulated as fixed combination in a single tablet. The thera‐
peutic regimen “all in one” is completely oral, without interferon, and is the unique that
provides three antiviral agents with direct action, each characterized by a different mechanism
of action. The 3D regimen ± RBV is indicated for 12 or 24 weeks for the treatment of patients
with GT-1 infection, while only paritaprevir/ritonavir and ombitasvir are indicated in GT-4
infection. The 3D regimen is also indicated in combination with RBV for 24 weeks in liver
transplant recipients with GT-1 infection, in patients coinfected with HIV-1, and in patients
receiving replacement therapy with opioids [116,117]. The safety and the efficacy of this
regimen were based on the results of six clinical trials: SAPPHIRE I, SAPPHIRE II, PEARL II,
PEARL III, PEARL IV, and TORQUOISE II.
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In the phase III SAPPHIRE I study, 631 treatment-naive adults with GT-1 infection were treated
for 12 weeks with 3D regimen in combination with RBV. The overall SVR12 was 96% [118].
The SAPPHIRE-II trial was conducted in 394 experienced patients with GT-1 infection without
cirrhosis. The SVR rates were 95.3% among patients with a prior relapse, 100% among patients
with a prior partial response, and 95.2% among patients with a prior null response [119].
The PEARL-III and PEARL-IV studies assessed the needing to include RBV in the 3D regimen
in treatment-naive adults with GT-1 infection. Clinical results showed that SVRs are similar in
GT-1a infection (99.5% vs 99% with or without RBV, respectively), while patients with GT-1b
infection achieved higher SVR12 in RBV group (97.0% vs 90.2%, with or without RBV,
respectively) [120]. Similar results were obtained in the PEARL-II, in experienced patients with
GT-1b infection [121]. The efficacy of paritaprevir/ritonavir and ombitasvir in treatment-naive
or experienced patients with GT-4 infection was proved in the PEARL-I. In this trial, 90.9% of
naive patients treated with 3D regimen without RBV and 100% of naive and experienced
patients treated with 3D regimen plus RBV achieved SVR12 [122].
In the TURQUOISE-II study, the efficacy and the safety of 12 or 24 weeks with 3D regimen
with RBV were assessed in patients with advanced disease and GT-1 infection. Ninety-two
percent of patients achieved SVR rates at 12 weeks, vs 96% at 24 weeks. Experienced patients
with GT-1a infection had a better response from 24 weeks of treatment [123]. The resistance
profile observed in these clinical trials seems to have little impact on the likelihood of achieving
SVR, given the low virological failure rates recorded. The 3D regimen has shown high efficacy
in patients with GT-1 infection (90–100%) and is well tolerated. The main adverse events
reported are moderate, mainly pruritus, fatigue, and headache [117,118]. This interferon-free
regimen is now being tested in different clinical trials in association with other DAAs.
New interferon-free combinations are under investigation in phase II/III clinical trials. New
compounds seem to have a more potent activity vs different genotypes than the DAAs of
second generation. The aim of these new therapies is to treat HCV infection through shorter
regimen. Grazoprevir and elbasvir ± sofosbuvir and sofosbuvir and ledipasvir plus GS-9451
are the most promising combination in clinical development. A six-week interferon-free oral
treatment regimen for HCV GT-1 infection will be likely available in the near future [124–127].
9.7. Special population
9.7.1. Liver transplanted patients
HCV infection is one of the risk factors of liver transplantation and an important cause of
morbidity and mortality in these patients [128]. HCV infection recurrence occurs in 50% of
subjects with detectable HCV RNA at the time of liver transplantation [31,129]. Dual therapy
based on peg-IFN/RBV was the standard of care and is associated with low SVR rates at 24
weeks (20–25%). Telaprevir and boceprevir improved SVR until 67%, but drug–drug interac‐
tion with immunosuppressive agents and serious adverse events can limit their use [8,130,131].
The introduction of DAAs has improved the efficacy of HCV therapy in patients before and
after liver transplantation.
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The first interferon-free regimen evaluated in pretransplant setting was 48 weeks of sofosbuvir
and RBV for all HCV genotypes. The posttransplant follow-up showed that sofosbuvir and
RBV prevented recurrence of HCV infection in 70% of patients [132]. Similar SVRs were
obtained in patients that had received liver transplant and then relapsed. The safety profile is
better than standard therapy on the base of adverse events reported [133,134].
The SOLAR-1 Phase II study analyzed the combination of sofosbuvir and ledipasvir for 12 or
24 weeks, in naive and experienced patients with a relapse of GT-1/GT-4 infection after liver
transplantation. The results showed that 96–98% of patients with F0-F3 fibrosis, 96% with
Child–Pugh–Turcotte A cirrhosis, 85–83% with Child–Pugh–Turcotte B cirrhosis, and 60–67%
with Child–Pugh–Turcotte C achieved the SVR12. The treatment was generally safe and well
tolerated [135]. Finally, in the CORAL-I study, the safety and the efficacy of 24 weeks of 3D
regimen with RBV were studied in 34 GT-1-infected liver transplant recipients with none or
mild fibrosis. The SVR was achieved in 97.1% of patients [136].
9.7.2. HIV-coinfected patients
Due to shared modalities of transmission, the infection with HCV is often widespread among
HIV-infected people. In the last decade, the rate of HCV coinfection was increased, and it has
been estimated that about 15–30% of HIV-infected patients are also infected with HCV. HIV/
HCV-infected patients are more difficult to treat since the coinfection decrease HCV clearance.
The standard of care of these patients was the combination of peg-IFN and RBV, but the
coadministration of several agents leads to increased drug–drug interaction and adverse
events and requires dose adjustment [137,138]. Similarly to that reported for HCV monoin‐
fected patients, the development of DAAs and interferon-free regimens has substantially
increased the treatment outcome. The combination of sofosbuvir and RBV was explored in
two studies. PHOTON-1 showed that 76%, 88%, and 67% of treatment-naive patients with
GT-1, GT-2, or GT-3 infection, respectively, achieved the SVR12. Sofosbuvir has minimal or
none interactions with a wide range of antiretroviral drugs, and treatment was well tolerated
[139,140]. Similar results have been obtained from PHOTON-2 [141]. The combination of
sofosbuvir and ledipasvir was evaluated in the ERADICATE study. In this trial, 100% of
untreated and antiretroviral-treated patients achieved the SVR12 [142]. Finally, the results
from TURQUOISE-I study showed that 93.5% of patients achieved SVR12 with 3D regimen
plus RBV [143].
10. Conclusions and challenges for the future
The advent of DAAs and interferon-free strategies has substantially improved the clinical
outcome in HCV therapy. Some interferon-free regimens have recently been licensed, and
some other are in clinical development. These new combinations have shown high SVR,
ranging from 90% to 100% even with shorter courses (8–12 weeks) of treatment, especially in
low responsive population with dual and triple therapies. Current studies focus on the clinical
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development of a new generation of DAAs, such as the combination of ABT 493 and ABT 530,
sofosbuvir, and GS-5816, gazoprevir, and elbasvir, which will be available in the near future
as therapeutic strategies with high efficacy and short regimen (4–8 weeks). However, both
scientific and economic unresolved issues are still present.
For the scientific perspectives, new and larger clinical studies are required in subjects infected
with GT-3, in treatment-experienced patients and at advanced stages of the disease, which
remain the most difficult subpopulations to be treated [144,145].
From the economic point of view, even though the new medications for hepatitis C are effective
disease modifiers and have the potential, in a long-term perspective, to eradicate the pathology,
the costs of new treatments are unlikely to be sustainable for the NHSs. Indeed, new pharma‐
ceutical policy and a global commitment are required to improve strategies of treatment and
price negotiation with pharmaceutical companies to move from a theoretical cost-effectiveness
approach to a practical cost-sustainable reality. Even if curing hepatitis C saves lives and
prevents a lot of downstream health care costs related to the progression of the disease,
including liver cancer or requirement of transplant, payers and politicians are in an uproar for
a variety of reasons, not least the fact that the drug is priced much higher in the United States
than in the rest of the world. For example, in Europe, where the government negotiates the
price, the cost of sofosbuvir is on the order of $55,000/patient. The ongoing discussion about
the sustainability of the new treatments demonstrates the limit of the current health technology
assessment classical approach. Indeed, the new products can be cost-effective in a long-term
perspective, considering the avoidance of further hospitalization and medicalization costs
related with transplantation. Until it will not be possible to reorganize the complete process
of therapy, to be able to capitalize the expected savings, the cost-effectiveness evaluation will
remain just a theory, posing concrete challenge to the sustainability of NHS systems. On the
other hand, the proposed cost of treatment is still considered too high in relation to the
prevalence of the pathology. This situation has opened the discussion on the necessity to find
new reimbursement approaches and new level of cooperation between different States. In
Europe, for example, bracket list price (min–max) for sofosbuvir has been proposed, to be
adjusted for instance by GDP/Pro-capita income (e.g., differential price), prevalence (price/
volume), and/or adaptive reimbursement considering genotyping, subclusters, and time to
event. None of the possible solutions have been implemented in a coordinated manner, but
the access to HCV new treatments stimulated, among health care decision makers, the
consciousness of the need of a new global synergistic approach.
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